Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Accounts Payables (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Accounts Payables for 15 consecutive years, with $1.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Accounts Payables rose 192.99% to $1.0 million in Q4 2025 year-over-year; TTM through Oct 2025 was $1.0 million, a 192.99% increase, with the full-year FY2025 number at $399204.0, down 45.7% from a year prior.
  • Accounts Payables was $1.0 million for Q4 2025 at PharmaCyte Biotech, up from $465209.0 in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $1.0 million in Q4 2025 to a low of $1983.0 in Q4 2021.
  • A 5-year average of $369197.2 and a median of $396989.5 in 2021 define the central range for Accounts Payables.
  • Biggest YoY gain for Accounts Payables was 43332.98% in 2022; the steepest drop was 96.19% in 2022.
  • PharmaCyte Biotech's Accounts Payables stood at $1983.0 in 2021, then skyrocketed by 43332.98% to $861276.0 in 2022, then plummeted by 85.35% to $126163.0 in 2023, then soared by 176.31% to $348595.0 in 2024, then surged by 192.99% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for PMCB's Accounts Payables are $1.0 million (Q4 2025), $465209.0 (Q3 2025), and $399204.0 (Q2 2025).